TFOS DEWS II Management and Therapy Report.

Show simple item record

dc.contributor.author Jones, Lyndon en
dc.contributor.author Downie, Laura E en
dc.contributor.author Korb, Donald en
dc.contributor.author Benitez-Del-Castillo, Jose M en
dc.contributor.author Dana, Reza en
dc.contributor.author Deng, Sophie X en
dc.contributor.author Dong, Pham N en
dc.contributor.author Geerling, Gerd en
dc.contributor.author Hida, Richard Yudi en
dc.contributor.author Liu, Yang en
dc.contributor.author Seo, Kyoung Yul en
dc.contributor.author Tauber, Joseph en
dc.contributor.author Wakamatsu, Tais H en
dc.contributor.author Xu, Jianjiang en
dc.contributor.author Wolffsohn, James S en
dc.contributor.author Craig, Jennifer en
dc.date.accessioned 2018-11-13T00:11:41Z en
dc.date.issued 2017-07-20 en
dc.identifier.issn 1542-0124 en
dc.identifier.uri http://hdl.handle.net/2292/44153 en
dc.description.abstract The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype. en
dc.format.medium Print-Electronic en
dc.language eng en
dc.relation.ispartofseries The ocular surface en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject Tears en
dc.subject Humans en
dc.subject Keratoconjunctivitis Sicca en
dc.subject Dry Eye Syndromes en
dc.title TFOS DEWS II Management and Therapy Report. en
dc.type Journal Article en
dc.identifier.doi 10.1016/j.jtos.2017.05.006 en
pubs.issue 3 en
pubs.begin-page 575 en
pubs.volume 15 en
dc.rights.holder Copyright: The author en
dc.identifier.pmid 28736343 en
pubs.end-page 628 en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Review en
pubs.subtype Journal Article en
pubs.elements-id 644685 en
pubs.org-id Medical and Health Sciences en
pubs.org-id School of Medicine en
pubs.org-id Ophthalmology Department en
dc.identifier.eissn 1937-5913 en
pubs.record-created-at-source-date 2017-07-25 en
pubs.dimensions-id 28736343 en


Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics